Related Experiment Video
Updated: Jun 13, 2026
12:36
Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry
Published on: June 26, 2018
Cytokines as therapeutic targets in SLE
1Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala SE-751 85, Sweden. lars.ronnblom@medsci.uu.se
Nature Reviews. Rheumatology
|May 5, 2010
Summary
Systemic lupus erythematosus (SLE) treatments are evolving. This review examines anticytokine therapies, including B-cell activating factor and interferon-alpha, for managing this autoimmune disease.
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Background:
- Systemic lupus erythematosus (SLE) is a complex autoimmune disease affecting multiple immune cells.
- Key cytokine pathways, including B-cell activating factor (BAFF), interferon-alpha (IFN-α), and tumor necrosis factor (TNF), are implicated in SLE pathogenesis.
- Prior success of anti-TNF therapy in rheumatoid arthritis has informed the development of targeted biologic agents for SLE.
Purpose of the Study:
- To review the rationale and current status of anticytokine therapies for SLE.
- To discuss biologic agents targeting cytokines and their receptors in SLE treatment.
- To present results from ongoing and completed clinical trials of anticytokine therapies.
Main Methods:
- Review of published literature on anticytokine therapies in SLE.
- Analysis of clinical trial data for biologic agents targeting cytokines in SLE.
- Discussion of experimental and emerging therapeutic strategies for SLE.
Main Results:
- Several biologic agents targeting key cytokines are in various phases of clinical development for SLE.
- Early-phase and some large-scale trials have reported preliminary efficacy data for anticytokine therapies.
- The efficacy of different anticytokine agents varies, with ongoing research to identify optimal targets and patient populations.
Conclusions:
- Anticytokine therapies represent a promising avenue for SLE treatment, targeting key inflammatory pathways.
- Further research and larger clinical trials are needed to establish the definitive efficacy and safety of these novel agents.
- Future SLE treatment strategies may involve personalized approaches based on cytokine profiles and targeted biologic interventions.
More Related Videos
10:21Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification
Published on: September 20, 2024
11:11Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment
Published on: January 24, 2020
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Cytotoxic T Cells-mediated Immune Response
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...